Personalised Medicine Strategies – Providing More Clinical Benefit

Current personalised medicine strategies provide limited clinical benefit – how do we do better? Luckily Dr Allan Jordan, the Director of Oncology Drug Discovery at leading CRO Sygnature Discovery, was on hand to explain how. Here's another chance to watch...

6 years ago
Clinical Development,Clinical Operations,Precision and Personalised Medicine

Personalised Medicine Strategies – Providing More Clinical Benefit

Current personalised medicine strategies provide limited clinical benefit – how do we do better? Luckily Dr Allan Jordan, the Director of Oncology Drug Discovery at leading CRO Sygnature Discovery, was on hand to explain how. Here's another chance to watch...

6 years ago

Key Challenges in Medicinal Chemistry and Biology

This year Proventa debuted its successful online event format for the first time, providing experts from across the sector with an online forum just as useful and educational as our physical events have always been. During the recent Medicinal Chemistry...

6 years ago
Biology

Key Challenges in Medicinal Chemistry and Biology

This year Proventa debuted its successful online event format for the first time, providing experts from across the sector with an online forum just as useful and educational as our physical events have always been. During the recent Medicinal Chemistry...

6 years ago

Weekly News Round-up – 17/7/20

In the news this week, despite significant alarms recently that GSK’s belantamab mafodotin could endanger patients’ eyes, the multiple myeloma drug has been approved by expert advisers. In other news, Novartis promises to make no profit from 15 of its COVID...

6 years ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 17/7/20

In the news this week, despite significant alarms recently that GSK’s belantamab mafodotin could endanger patients’ eyes, the multiple myeloma drug has been approved by expert advisers. In other news, Novartis promises to make no profit from 15 of its COVID...

6 years ago

Weekly News Round-up – 10/7/20

In the news this week, the Trump Administration has made another deal to acquire all initial doses of a potential COVID-19 drug, in this case Regeneron’s REGN-COV2. This follows their acquisition of the first batches of Gilead’s remdesivir last week....

6 years ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 10/7/20

In the news this week, the Trump Administration has made another deal to acquire all initial doses of a potential COVID-19 drug, in this case Regeneron’s REGN-COV2. This follows their acquisition of the first batches of Gilead’s remdesivir last week....

6 years ago

Clinical Trial Continuity and the Impact of COVID-19

Here's a second chance to catch the fascinating keynote panel discussion lead by Josh Rose, VP GM Virtual Trial Solutions Business, IQVIA and joined by Eli Lilly and Co., EMD Serono/Merck KGaA and Janssen. See how you can prepare for...

6 years ago
Clinical Development

Clinical Trial Continuity and the Impact of COVID-19

Here's a second chance to catch the fascinating keynote panel discussion lead by Josh Rose, VP GM Virtual Trial Solutions Business, IQVIA and joined by Eli Lilly and Co., EMD Serono/Merck KGaA and Janssen. See how you can prepare for...

6 years ago

Weekly News Round-up – 3/7/20

Big news this week, with the U.S. administration buying up remdesivir’s stock for the next three months, ensuring no other country will receive any. In other news, Pfizer and BioNTech’s own covid drug has shown promising results in early trials,...

6 years ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 3/7/20

Big news this week, with the U.S. administration buying up remdesivir’s stock for the next three months, ensuring no other country will receive any. In other news, Pfizer and BioNTech’s own covid drug has shown promising results in early trials,...

6 years ago
Previous Page Showing 276 out of 323 Next Page
Working With us

Interested?
Reserve your space